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Abstract
Introduction: A primary ureteral stump tumor after a nephrectomy is rare; urothelial carcinoma of the ureteral
stump after a nephrectomy for renal cell carcinoma is even rarer. A thorough review of the literature indicated that
only seven cases have previously been reported. In this study, we report the first Taiwanese case of urothelial
carcinoma of the ureteral stump after a nephrectomy. It is also the first female case in the literature. The
relationship between inflammatory genes, medication history and ureteral stump carcinoma after a nephrectomy
for renal cell carcinoma has not been reported.
Case presentation: A 72-year-old Asian Taiwanese women with chronic hepatitis C, liver cirrhosis and chronic
kidney disease underwent a hand-assisted laparoscopic radical nephrectomy in 2001 due to renal cell carcinoma.
Nine years later, she was diagnosed with ureteral stump urothelial carcinoma. Genetic and medication surveys
were performed. Importantly, our patient had taken Chinese herbal drugs for more than 10 years and the
inflammatory gene, Cox-2, was highly expressed in this patient. This is the first report to study the relationship
between the Cox-2 gene and ureteral stump carcinoma after a nephrectomy for renal cell carcinoma.
Conclusion: Long-term multiple use of Chinese herbal drugs could be one of the important risk factors for
developing urothelial cancer. Close functional coupling between Chinese herbal drugs, Cox-2 gene activation and
urothelial cancer should be further investigated.
Introduction
The incidence of urothelial carcinoma in the ureter is
rare, accounting for less than 5% of all urothelial neo-
plasms. It often occurs in the lower third of the ureter
and the recurrence rate is relatively high [1]. A primary
tumor of the ureteral stump after a nephrectomy is
infrequently observed. Moreover, a primary tumor of
the ureteral stump after a nephrectomy for a renal cell
carcinoma (RCC) is extremely rare. A thorough review
of the literature indicated that only seven cases have
previously been reported of ureteral stump carcinoma
after a nephrectomy for an RCC [2-8]. This eighth
observed case is the first reported case in Taiwan.
Prostaglandins are important inflammatory molecules
involved in the pathogenesis of cancer. Prostaglandins
can be metabolized from arachidonic acid by the cycloox-
ygenases 1 (Cox-1) and cyclooxygenases 2 (Cox-2). Cox-1
is a constitutive enzyme whereas Cox-2 is an inducible
enzyme that is activated by extracellular stimulations
including cytokines [9], growth factors [10] and endotox-
ins [11]. Several lines of evidence indicate that Cox-2 is
one of the most critical enzymes in tumor metastasis.
Cox-2 overexpression may lead to the cancer cell inva-
siveness of human breast cancer cells [12]. Clinical stu-
dies have extensively documented that Cox-2 inhibitors,
such as nonsteroidal anti-inflammatory drugs, can reduce
the incidence of colon cancer [13].
To the best of our knowledge, the relationship between
inflammatory genes, medication history and ureteral
stump carcinoma after a nephrectomy for an RCC has
not been reported. We therefore conducted a prospective
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reported case of ureteral stump carcinoma after a
nephrectomy for an RCC in Taiwan.
Case presentation
A 72-year-old Asian Taiwanese woman with intermittent,
painless, total gross hematuria visited the Department of
Urology of our hospital in 2010. She had been diagnosed
with chronic hepatitis C and stage III chronic kidney dis-
ease for 10 years and has regular follow-up. In 2001 (nine
years ago), a routine ultrasound examination showed a
left renal tumor. Computed tomography (CT) confirmed
the diagnosis (Figure 1). She then was transferred to our
Department of Urology and underwent a hand-assisted
laparoscopic radical nephrectomy. The pathological
reports revealed an RCC of stage T1N1M0, which cov-
ered the cortex and medulla with central areas of necro-
sis and hemorrhage, measuring 11.0 cm × 7.0 cm ×
4.0 cm. The calyx segment of the collecting system was
also included. Her ureter was not dilated and its mucosa
was not remarkable. Fortunately, her ureter was free
from cancer tissues. After the operation, she received
regular follow-up.
At the beginning of 2010, nine years later, our patient
had one episode of gross hematuria. The results of
examinations such as urine cytology and cystoscopy
were normal. A CT scan showed two renal stones in her
right kidney without other abnormalities. The hematuria
subsided spontaneously. Two months later, another epi-
sode of gross hematuria occurred. This time, clot forma-
tion was noted in her urine. Once again, the symptoms
subsided spontaneously. Cystoscopy revealed whitish
debris coating the left ureter orifice; no gross bladder
tumor was seen. A ureter catheter could not be inserted
into her left ureter due to a ureterovesical junction stric-
ture. Thus, retrograde pyelography with a cone tip uret-
eral catheter was tried, but also failed. However, CT
scans showed a prominent soft tissue mass at the ure-
terovesical junction. The middle and lower third parts
of her residual left ureter were dilated (Figure 2).
According to the imaging, a urothelial carcinoma of the
ureter stump was highly suspected. Therefore, a uretero-
scopic examination and biopsy was performed using a
fiberoptic rigid ureteroscope. We tried to use a guide-
wire to pass the ureteral orifice cystoscopically but the
guidewire could only be progressed for less than 1 cm.
The ureteroscope was therefore inserted without intra-
mural dilatation of the ureterovesical junction and it
was only possible to examine the ureter up to less than
1 cm from the ureterovesical junction. The biopsy was
thus taken from the lower ureter where it is close to the
ureterovesical junction. The pathological report showed
a high-grade infiltrating urothelial carcinoma. The
tumor invaded the subepithelial connective tissue
(lamina propria) and the pathologic staging of the pri-
mary tumor was T1. A radical operation (ureterectomy
with ipsilateral bladder cuff excision or a cystectomy) or
systemic chemotherapy were suggested. Without family
support, our patient had been in a depressed state for a
long time. With consideration of the multiple coexisting
systemic diseases, such as liver cirrhosis, chronic kidney
disease, gallbladder stones, facial palsy, hypertension and
Figure 1 Axial view of contrast-enhanced computed tomography scans revealing a left renal tumor.
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both treatment options. She asked for supportive treat-
ment only.
To further identify the possible risk factors contribut-
ing to the urothelial carcinoma of the ureteral stump, we
checked the medication history of our patient. As shown
in Table 1, our patient had taken several different kinds
of drugs for more than 10 years. These were cephalos-
porin, nitroxoline, sulfonamide, levofloxacin for urinary
tract infection, atenolol, amlodipine, solantin for hyper-
tension, atorvastatin for hyperlipidemia, ursodeoxycholic
acid for liver cirrhosis and Chinese herbal drugs for mul-
tiple somatic complaints. Importantly, although our
patient had taken Chinese herbal drugs for more than 10
years, the compositions of these drugs remain unclear.
Long-term multiple use of Chinese herbal drugs may
influence inflammatory reactions. We therefore com-
pared gene expression level of Cox-2 between this patient
and patients with calcium nephrolithiasis. Real-time poly-
merase chain reaction experiments indicated that a high
level of expression of the Cox-2 g e n ew a ss e e ni no u r
patient with the urothelial carcinoma of the ureteral
stump (Figure 3).
Discussion
An RCC is a common renal parenchymal malignant
tumor. RCCs originate from the proximal renal tubular
epithelium in the renal cortex. Urothelial carcinoma is a
common cancer of the urinary bladder. It may also occur
in the collecting system of the upper urinary tract, such
as the renal pelvis and ureter. The causes of RCCs are
unknown; environmental exposure to asbestos, solvents
Figure 2 Coronal view of computed tomography scans revealing a prominent soft tissue at the left ureterovesical junction. The middle
and lower third parts of her residual ureter were dilated.
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implicated. The causes of urothelial cancer include smok-
ing and occupational exposure to chemicals, dyes, rub-
bers, petroleum, leathers and printing materials; people
w h oa r ee x p o s e dt ot h e s ef o ral o n gt i m ea r eah i g h - r i s k
group for developing urothelial cancers. Genetic changes
may also occur throughout the urothelium.
A primary ureteral stump tumor can be defined as a
tumor occurring in the closed ureteral stump after a
nephrectomy for either benign or malignant disease
other than a urothelial tumor. Clinically, both diagnoses
and treatments for a ureteral stump tumor are still elu-
sive. Furthermore, a primary urothelial carcinoma of the
ureteral stump after a nephrectomy for an RCC is
Table 1 Medication history and the possible side effects
Drug Disease/disturbance Side effect
Cefradine Urinary tract infection Hypersensitivity, elevated liver enzyme, diarrhea
Nitroxoline Urinary tract infection Gastrointestinal intolerance, urine coloration
Sulfonamide Urinary tract infection Hypersensitivity, folic acid deficiency, hematological abnormality
Levofloxacin Urinary tract infection Diarrhea, tendinitis, seizure neuropathy, elevated liver enzyme
Atenolol Hypertension Bradycardia, cough, Raynaud’s syndrome
Amlodipine Hypertension Flush, tachycardia, edema
Solantin Thromboembolism Dizziness, abdomen distress, angina, headache
Ursodeoxycholic acid Liver cirrhosis Gastrointestinal disturbance
Atorvastatin Hyperlipidemia Gastrointestinal disturbance, elevated liver enzyme, myopathy, neuropathy
Chinese herb drugs Multiple somatic complaints Unknown
Patients` No. 1 2                                3
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Figure 3 The Cox-2 gene expression level was checked in patients with calcium nephrolithiasis (patients 1 and 2) or with a urothelial
carcinoma of the ureteral stump (patient 3).
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literature (Table 2). Our case is the first case in Taiwan
and is the first female case in the literature.
In the reported cases, the mean interval between the
nephrectomy and detection of the ureteral stump
tumor was 7.1 ± 7.0 years, ranging from 0.9 years to 23
years. In a report by Kim et al., the interval between
the detection of a ureteral stump tumor and the
nephrectomy for benign renal disease was 76.5 months
[14]. Although the etiology of a ureteral stump tumor
remains to be seen, metaplastic changes caused by
chronic inflammation due to infection or stone irrita-
tion, malignant metamorphosis caused by leukoplakia
[ 1 5 ] ,e x p o s u r et oc a r c i n o g e n i cs u b s t a n c e s ,ah i g hr i s k
of genetic cancer susceptibility and several others fac-
tors are very likely to be associated with this rare dis-
ease. Chronic inflammation is often related to
squamous cell metaplasia resulting in squamous cell
carcinoma [16]. After a nephrectomy, the ureteral
stump is no longer exposed to the chemical carcino-
gens which are present in the urine; resulting in a low
possibility of developing cancer from a urinary carcino-
gen. Genetic hypersensitivity, mutation or pharmacolo-
gical carcinogenetic effects provide other possibilities
for cancer development. Our patient had experienced
chronic recurrent urinary tract infection, with episodes
occurring three to four times every year. Several
reports have indicated the correlation between Chinese
herbal drugs and urothelial carcinoma [17-20]. A
patient with liver cirrhosis, such as ours, may have a
reduced ability to metabolize herbal drugs due to
damage to the liver. Therefore, the side effects of Chi-
nese herbal drugs may be amplified and accumulate.
In addition to chemical carcinogenesis from Chinese
herbal drugs, genetic effects might contribute to malignant
tumors. Cox-2 polymorphism has been shown to be a pre-
dictive marker of survival in non-small cell lung cancer
patients treated with chemoradiotherapy or radiotherapy
[19,21,22]. Our results, consistent with previous reports,
indicated that a high level of Cox-2 gene expression may
be associated with the pathogenesis of the primary ureteral
stump tumor. The Cox-2 gene can be evoked by a variety
of chemical compounds, including alkaloids, polysacchar-
ides and heavy metals. Chinese herbal drugs contain a
large amount of alkaloids, polysaccharides and heavy
metals. Long-term use of Chinese herbal drugs may result
in physiological dysfunction. Another postulation by Klee
and colleagues [5] was that a prior bladder carcinoma
could make reflux implantation into the ureteral stump
more likely, even though no significant vesicoureteral
reflux was noted. In other words, a history of previous
cancer elsewhere in the urinary tract was thought to be a
high risk factor for ureteral stump cancer. Unlike the
assumption proposed by Klee and colleges, the patient in
our case had no history of bladder cancer, but her ureteral
stump had possibly been exposed to urinary carcinogens
for more than 10 years because of vesicoureteral reflux.
Conclusions
Urothelial carcinoma of the ureteral stump after a
nephrectomy for an RCC is rare. A ureteral excision
made during a nephrectomy should be as large as possi-
ble for benign disease or a non-urothelial tumor. If the
ureter is left after the nephrectomy, the ureteral stump
should be evaluated and followed-up carefully. Long-
term multiple use of Chinese herbal drugs could be one
of the important risk factors for developing urothelial
cancer. Close functional coupling between Chinese her-
bal drugs, Cox-2 gene activation and urothelial cancer
should be further investigated.
Consent
Oral and written informed consent was obtained from
the patient and her next-of-kin for publication of this
case report and any accompanying images. A copy of
the written consent is available for review by the Editor-
in-Chief of this journal.
Acknowledgements
This study was supported by funding from an Excellence for Cancer
Research Center grant, Department of Health, Executive Yuan, Taiwan, R.O.C.
(DOH101-TD-C-111-002).
Author details
1Department of Healthcare Management, Yuanpei University, HsinChu,
Taiwan.
2School of Post-baccalaureate Medicine, Kaohsiung Medical
University, Taiwan.
3Department of Medical Genetics, Kaohsiung Medical
University, Taiwan.
4Department of Urology, Kaohsiung Medical University
Hospital, Taiwan.
5Cancer center, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan.
6Department of Urology, Kaohsiung Medical University,
Taiwan.
Authors’ contributions
WPC drafted the article. WPC, TMC and YSW analyzed and interpreted the
patient data. MHL photographed and interpreted the pathologic findings.
WCC, MFH, WPC and SJC took part in the critical revision and YHC took part
in the diagnosis, treatment of the patient and gave final approval of the
manuscript. All authors have made substantive intellectual contributions to
Table 2 Patient data for a ureteral stump tumor after a
nephrectomy for a renal cell carcinoma
Case Age Sex Interval
(years)
Side Reference
1 75 M Two and a half Right [4]
2 62 M Two and a half Right [5]
3 70 M Seven Right [3]
4 49 M 23 Left [2]
5 88 M Six Left [6]
6 64 M Six Right [8]
7 68 M 0.9 Right [7]
8 72 F Nine Left Present case
Chang et al. Journal of Medical Case Reports 2012, 6:44
http://www.jmedicalcasereports.com/content/6/1/44
Page 5 of 6this study and to the manuscript and have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 October 2011 Accepted: 30 January 2012
Published: 30 January 2012
References
1. Pohar KS, Sheinfeld J: When is partial ureterectomy acceptable for
transitional-cell carcinoma of the ureter? J Endourol 2001, 15:405-408,
discussion 409.
2. Cher ML, Milchgrub S, Sagalowsky AI: Transitional cell carcinoma of the
ureteral stump 23 years after radical nephrectomy for adenocarcinoma.
J Urol 1993, 149:106-108.
3. Gohji K, Ueno K, Higuchi A, Fujii A: A case of asynchronous renal cell
carcinoma and urothelial cancer of the urinary bladder and left ureter.
Hinyokika Kiyo 1993, 39:927-930.
4. Grey LF, Sorial RF, Levin HJ: Transitional cell carcinoma in ureteral stump
after radical nephrectomy for renal cell carcinoma. Urology 1987,
29:209-210.
5. Klee LW, Adams MC, Foster RS: Ureteral stump transitional cell carcinoma
in a patient with recurrent superficial bladder cancer: an argument for
complete nephroureterectomy in selected patients. J Urol 1990,
144:972-973.
6. Mitsui K, Yamada Y, Taki T, Akahori M, Kato K, Honda N, Fukatsu H, Kawai Y,
Yoshikawa K: A case of asynchronous renal cell carcinoma, hepatocellular
carcinoma and residual ureteral cancer. Hinyokika Kiyo 1998, 44:583-586.
7. Nagatsuma K, Tachibana M, Miyakawa A, Asanuma H, Murai M: Transitional
cell carcinoma of ureteral stump after radical nephrectomy for renal cell
carcinoma. Int J Urol 1999, 6:627-629.
8. Suzuki T, Tsuchiya N, Otomo R, Kakinuma H, Satoh S, Sato K, Ogawa O,
Kato T: Primary tumor of the ureteral stump following a nephrectomy
for renal cell carcinoma. Int J Urol 1999, 6:41-43.
9. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM:
Molecular cloning of human prostaglandin endoperoxide synthase type
II and demonstration of expression in response to cytokines. J Biol Chem
1993, 268:9049-9054.
10. Chen LC, Chen BK, Chang JM, Chang WC: Essential role of c-Jun induction
and coactivator p300 in epidermal growth factor-induced gene
expression of cyclooxygenase-2 in human epidermoid carcinoma A431
cells. Biochim Biophys Acta 2004, 1683:38-48.
11. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA
1992, 89:7384-7388.
12. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A: COX-2
overexpression increases motility and invasion of breast cancer cells. Int
J Oncol 2005, 26:1393-1399.
13. Hyde CA, Missailidis S: Inhibition of arachidonic acid metabolism and its
implication on cell proliferation and tumour-angiogenesis. Int
Immunopharmacol 2009, 9:701-715.
14. Kim YJ, Jeon SH, Huh JS, Chang SG: Long-term follow-up of ureteral
stump tumors after nephrectomy for benign renal disease. Eur Urol 2004,
46:748-752.
15. Park JY, Park J, Ku JH, Kim HH: Transitional cell carcinoma in a remnant
ureter after retroperitoneoscopic simple nephrectomy for benign renal
disease. J Korean Med Sci 2009, 24:992-994.
16. Holmang S, Lele SM, Johansson SL: Squamous cell carcinoma of the renal
pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol
2007, 178:51-56.
17. Cheung TP, Xue C, Leung K, Chan K, Li CG: Aristolochic acids detected in
some raw Chinese medicinal herbs and manufactured herbal products-a
consequence of inappropriate nomenclature and imprecise labelling?
Clin Toxicol (Phila) 2006, 44:371-378.
18. Mason RG, Donaldson D: Chinese herbal nephropathy and urothelial
malignancy. J R Soc Promot Health 2002, 122:266-267.
19. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M,
Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P,
Vanherweghem JL: Urothelial carcinoma associated with the use of a
Chinese herb (Aristolochia fangchi). N Engl J Med 2000, 342:1686-1692.
20. Shum S: Chinese herbs and urothelial carcinoma. N Engl J Med 2000,
342:1686-1692.
21. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L:
Cyclooxygenase-2 genetic variants are associated with survival in
unresectable locally advanced non-small cell lung cancer. Clin Cancer Res
2010, 16:2383-2390.
22. Grimminger PP, Stöhlmacher J, Vallböhmer D, Schneider PM, Hölscher AH,
Metzger R, Danenberg PV, Brabender J: Prognostic significance and
clinicopathological associations of COX-2 SNP in patients with nonsmall
cell lung cancer. J Oncol 2009, 2009:139590.
doi:10.1186/1752-1947-6-44
Cite this article as: Chang et al.: Cox-2 gene overexpression in ureteral
stump urothelial carcinoma following nephrectomy for renal cell
carcinoma: a case report. Journal of Medical Case Reports 2012 6:44.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chang et al. Journal of Medical Case Reports 2012, 6:44
http://www.jmedicalcasereports.com/content/6/1/44
Page 6 of 6